# TRUSELTIQ® (infigratinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/infigratinib

> The PDUFA target action date for TRUSELTIQ® (infigratinib), sponsored by BridgeBio Pharma, Inc. (BBIO), is February 4, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the TRUSELTIQ® (infigratinib) PDUFA date?

The PDUFA target action date for TRUSELTIQ® (infigratinib), sponsored by BridgeBio Pharma, Inc. (BBIO), is February 4, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "- Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review." Last confirmed October 29, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/infigratinib)

Source: Press release filed with the SEC (EX-99), accession 0001743881-26-000033, https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/infigratinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | TRUSELTIQ® (infigratinib) |
| Codes |  |
| Sponsor | BridgeBio Pharma, Inc. (BBIO) https://sec-api.dev/companies/bbio/catalysts |
| Indications | [children with achondroplasia](https://sec-api.dev/indications/children-with-achondroplasia), achondroplasia, the efficacy, safety |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### early 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-04-29, last confirmed 2025-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "•BridgeBio expects topline results of PROPEL 3 in early 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102985): "BridgeBio expects topline results of PROPEL 3 in early 2026." https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-060085): "BridgeBio expects to achieve last participant - last visit in the second half of 2025 and topline results in early 2026." https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-ex99_1.htm

### February 12, 2026: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 3.
- First seen 2025-08-05, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001743881-26-000009): "On February 12, 2026, we reported positive Phase 3 Topline results from our PROPEL 3 study for oral infigratinib with the first statistically significant improvements in body proportionality in achondroplasia." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "-PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia expects topline results in early 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-102985): "- PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia expects topline results in early 2026." https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-004995): "PALO ALTO, CA - February 12, 2026 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced positive topline results from PROPEL 3, the global" https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/ef20065539_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-000971): "- LPLV achieved for PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia, with topline results expected by end of Q1 2026; LPI achieved for the Phase 2 portion of ACCEL 2/3, the registrational study of infigratinib for children with hypochondroplasia" https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/ef20062706_ex99-1.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: achondroplasia, the efficacy, safety.
- First seen 2026-02-12, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-004995): "These forward-looking statements, including express and implied statements relating to the topline results from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, the efficacy, safety and the clinical, therapeutic and market potential of oral infigratinib, our expected interactions with regulatory authorities, our plans to submit a New Drug Application and Marketing Authorization Application for infigratinib to the FDA and EMA, as applicable, in the second half of 2026 for treatment of achondroplasia" https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/ef20065539_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000018): "•The Company intends to submit an NDA to the FDA in the third quarter of 2026, and an MAA to the EMA in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-2026331xex991.htm

### August 4, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-10-29, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001743881-26-000034): "•On August 4, 2026, we submitted our NDA to the FDA for low-dose infigratinib for achondroplasia." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm
- SEC Form 10-Q (accession 0001743881-26-000034): "On August 4, 2026, we submitted our NDA to the FDA for low-dose infigratinib for achondroplasia." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm

### October 6, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: children with achondroplasia.
- First seen 2026-10-13, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-039334): "PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia." https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm

### February 4, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-10-13, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "- Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "Oral infigratinib for achondroplasia PDUFA date set for February 4, 2027, with Priority Review; MAA submitted to EMA U.S. launch upon FDA approval" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "•The FDA accepted the Company's NDA for oral infigratinib and granted Priority Review, assigning a PDUFA target action date of February 4, 2027." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-039334): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 4, 2027, and BridgeBio is prepared to launch oral infigratinib upon approval." https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-039334): "that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, including by the FDA's February 4, 2027 PDUFA target action date, or may require additional data, studies or other information" https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm
- SEC Form 10-Q (accession 0001743881-26-000034): "The FDA accepted our NDA for filing, granted Priority Review and assigned a PDUFA target action date of February 4, 2027, for infigratinib." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-039334): "- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia" https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm

### late 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-08-10, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "- The oral encaleret and oral infigratinib franchises continue to expand beyond their first indications: RECLAIM-HP in chronic hypoparathyroidism has begun screening patients with topline data anticipated in late 2027 or early 2028, CALIBRATE-PEDS in pediatric ADH1 has completed enrollment in its first cohort, and a Phase 2 update in hypochondroplasia is expected in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "The MAA will be based on the final analysis of the Phase 3 FORTIFY study at Month 36, with topline results expected late 2027/early 2028." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm

## Same indication

- [YUVIWEL® (navepegritide)](https://sec-api.dev/pdufa/navepegritide) (ASND)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/infigratinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TRUSELTIQ® (infigratinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/infigratinib

```bibtex
@misc{secapidev_pdufa_infigratinib_20261116,
  title        = {TRUSELTIQ® (infigratinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/infigratinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_infigratinib_20261116","title":"TRUSELTIQ® (infigratinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/infigratinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
